2021 年 4 月至 8 月，挪威针对 Delta（B.1.617.2）变异株的感染疫苗效力。
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021.
机构信息
Department of infectious disease control and vaccines, Norwegian Institute of Public Health, Oslo, Norway.
ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden.
出版信息
Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100793.
Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0-27.4) and 64.6% (95% CI: 60.6-68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4-58.3) and 84.4% (95%CI: 81.8-86.5) against the Alpha variant.
在这项基于人群的队列研究（n=4204859）中，共发现 5430 例（0.13%）Delta 变异株感染者，其中 84 例住院。与 Alpha 变异株相比，部分接种疫苗者对实验室确诊感染 Delta 变异株的疫苗有效性为 22.4%（95%置信区间：17.0-27.4），完全接种疫苗者为 64.6%（95%置信区间：60.6-68.2）；而对 Alpha 变异株的疫苗有效性分别为 54.5%（95%置信区间：50.4-58.3）和 84.4%（95%CI: 81.8-86.5）。
Zotero 插件